ILCN Lung Cancer News
ILCN Lung Cancer News


  • Adjuvant EGFR-TKI for Resected NSCLC: Who, When, and Where?

    Adjuvant EGFR-TKI for Resected NSCLC: Who, When, and Where?

    Evolving Standards of Care

    By Si-Yang Liu, MD, and Yi-Long Wu, MD Posted: November 12, 2019 Dr. Si-Yang Liu Dr. Yi-Long Wu In the twentieth century, adjuvant chemotherapy became the standard of care for resected NSCLC based on several clinical trials including IALT, JBR.10, ANITA, and a meta-analysis of individual patient data from the LACE trial. Adjuvant chemotherapy increased…